Share this Page:
A recent study by researchers in China, and published in the Journal of Cancer, assessed the Immunoscore system to determine if it can predict survival in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs).
The presence of various protein receptors on the cancer cells were analysed. Levels of protein receptors for CD8, CD4, Treg, PD-1, and PD-L1 were found to be raised in mRCC patients and were determined to be independent predictive factors for overall survival. Immunoscore was established containing these immunological factors.
In summary, Immunoscore was found to be a powerful prognostic factor for overall survival and progression-free survival in patients with mRCC treated with TKIs. The researchers suggest that Immunoscore can be used to supplement the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score to predict outcome in patients with mRCC.
